Brief Profile

Memantine – a new class
Memantine is the first representative of a new class of Alzheimer drugs – a moderate affinity NMDA-receptor antagonist. Brief Profile

Service for Professionals

Download a live recording of Dr. Jeffrey Cummings, inventor of the NPI scale, discussing "relevance, assessment, and treatment of behavioral disturbances in Alzheimer's disease" (for professionals)

How does Memantine work? A new video clip explains the mechanism of action of memantine.

Frequently Asked Questions (FAQ)

Where is memantine available? Are there any side effects?  We offer an overview of the most frequently asked questions.

• News
• News Releases
• Newsletter
• New Memantine Literature

• Brief Profile
• Product characteristics

• Mode of Action

• Studies & Literature
• Clinical Studies
• Preclinical Data
• Further literature

• FAQ

• Contact

If you can read this text, your browser browser does not the support the Web standard Cascading Style Sheets (C S S) for graphic display. We use C S S for page formatting, please don’t wonder if the pages display somewhat screwed lacking C S S.

Innovation for Alzheimer Patients. Retrieved July 4, 2008, 08:58 PM, from Memantine.com Web site: http://www.memantine.com/en/

© 2008 Merz Pharmaceuticals. All Rights Reserved. Individuals are permitted to electronically copy material published on this site and to make print-outs thereof, solely for their personal information, provided that both the copyright notice and the permission notice appear thereon and provided that the materials are not modified.